# GMP, inspections, Form 483s and warning letters

Source: https://onco.cc/technologies/pharmaceutical-gmp-inspections/  
OnCo record `pharmaceutical-gmp-inspections` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Every cancer drug plant works under Good Manufacturing Practice rules and is inspected. When inspectors find problems they write them up (a Form 483 in the United States), and if the answers are poor a public warning letter, an import ban or a court order can follow. Those actions protect patients, and they are also how shortages begin.

## Summary

Good Manufacturing Practice (GMP) is the body of law and guidance that says how a medicine must be made and tested: in the United States 21 CFR 210 and 211 for drugs, the 600 series for biologics, 1271 for cell and tissue products and 212 for PET drugs; in the EU, EudraLex Volume 4 with its annexes (Annex 1 on sterile products was rewritten in 2022, Annex 2 covers biologicals, Annex 3 radiopharmaceuticals); internationally the ICH Q7 to Q12 guidelines and the PIC/S scheme that lets inspectorates rely on each other. The EU and US operate a mutual recognition agreement for GMP inspections, so each accepts the other's inspections of plants in their territories.

Inspection outcomes follow a ladder. An FDA investigator lists observations on Form FDA 483 at the end of an inspection; the firm has fifteen working days to respond; unresolved or serious findings lead to a Warning Letter, published on the FDA website, and for foreign plants to an Import Alert that stops products at the border; the worst cases end in a consent decree overseen by a court. Data integrity (complete, attributable, original records) has been the most common theme of recent letters to Indian and Chinese API and generic plants, and sterile assurance the most common at injectable plants. The same actions that take a bad plant offline remove its share of supply, which is why almost every recent oncology shortage traces back to an inspection finding at a plant with few competitors, and why the FDA now weighs shortage risk when it acts. OnCo records inspection outcomes only as this class of event and links to the public letters database rather than naming individual findings.

## Fields

- Kind: Technology
- Status: standard-of-care
- Last checked: 2026-09-17
- Tags: manufacturing-wave
- Principle: Codified manufacturing standards enforced by inspection, with graded public enforcement that trades short-term supply against long-term quality.
- Since: 1963
- Strengths: Public, searchable enforcement record; Mutual recognition spreads inspection capacity; Quality-by-design and ICH Q12 let approved changes move faster
- Limitations: Foreign inspections are infrequent; Enforcement at a sole supplier creates shortages; Compliance cost drives exit from low-margin drugs

## Sources

- 21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
- EudraLex Volume 4: EU guidelines for good manufacturing practice: https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
- FDA warning letters database: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
- FDA: inspection observations (Form 483): https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
- PIC/S: https://picscheme.org/

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Antibody manufacturing (CHO bioprocessing)](https://onco.cc/technologies/monoclonal-antibody-manufacturing/), [BCG manufacturing and the bladder cancer BCG shortage](https://onco.cc/technologies/bcg-vaccine-manufacturing/), [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Cell-therapy release and potency testing](https://onco.cc/technologies/cell-therapy-release-testing/), [Generic oncology drug supply and shortage mitigation](https://onco.cc/technologies/generic-drug-shortage-response/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Oral solid dose manufacturing (tablets and capsules)](https://onco.cc/technologies/oral-solid-dose-manufacturing/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/), [Small-molecule API synthesis](https://onco.cc/technologies/small-molecule-api-synthesis/), [The ADC supply chain (antibody, payload-linker, conjugation, fill)](https://onco.cc/technologies/adc-supply-chain/)
- companies: [Catalent (Novo Holdings)](https://onco.cc/companies/catalent/), [Intas Pharmaceuticals (Accord Healthcare)](https://onco.cc/companies/intas/), [Lonza](https://onco.cc/companies/lonza/), [Novartis](https://onco.cc/companies/novartis/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [Samsung Biologics](https://onco.cc/companies/samsung-biologics/), [WuXi Biologics](https://onco.cc/companies/wuxi-biologics/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/)

---
JSON: https://onco.cc/api/v1/entities/pharmaceutical-gmp-inspections.json